B Group, Inc. reported 19 holdings worth US$162M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
B Group, Inc. reported 19 holdings worth US$162M as of Sep 30, 2026. Largest: ADMA Biologics Inc, Sensei Biotherapeutics, Inc. and Palisade Bio, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 19
- Value as reported
- US$162M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| ADMA Biologics Inc | 3.26M | US$32.7M | 20.2% |
| Sensei Biotherapeutics, Inc. | 610K | US$18.1M | 11.2% |
| Palisade Bio, Inc. | 11.4M | US$15.4M | 9.5% |
| NRX Pharmaceuticals, Inc. | 4.28M | US$12.5M | 7.7% |
| Zai Lab Ltd. | 451K | US$11.9M | 7.3% |
| Praxis Precision Medicines, Inc. | 33,237 | US$9.68M | 6.0% |
| Sight Sciences, Inc. | 970K | US$9.08M | 5.6% |
| Taysha Gene Therapies, Inc. | 1.8M | US$8.77M | 5.4% |
| Iovance Biotherapeutics, Inc. | 425K | US$6.3M | 3.9% |
| Structure Therapeutics, Inc. | 180K | US$5.63M | 3.5% |
| Spyre Therapeutics, Inc. | 62,500 | US$5.56M | 3.4% |
| Cellectis S.A. | 3.28M | US$4.96M | 3.1% |
| Aura Biosciences, Inc. | 764K | US$4.8M | 3.0% |
| Bright Minds Biosciences Inc. | 95,000 | US$4.73M | 2.9% |
| Oruka Therapeutics, Inc. | 55,000 | US$4.58M | 2.8% |
| Assembly Biosciences, Inc. | 176K | US$4.13M | 2.5% |
| Ultragenyx Pharmaceutical Inc. | 135K | US$2.03M | 1.3% |
| Foghorn Therapeutics Inc. | 200K | US$714K | 0.44% |
| Q32 Bio Inc. | 65,000 | US$538K | 0.33% |
Source
Download original · View original at SEC